KCTBASE

Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis.

Jung, Jin-A; Lim, Hyeong-Seok

Pharmacogenomics
2014Jan ; 15 ( 1 ) :49-60.

PMID : 24329190

저자 상세정보

Jung, Jin-A -
Lim, Hyeong-Seok -

ABSTRACT

AIM: Tamoxifen is one of the most commonly used endocrine therapeutic agents for breast cancer. Although many studies have examined whether the treatment outcomes of tamoxifen for breast cancer differ according to CYP2D6 genotype, the study results have been inconsistent, and the role of CYP2D6 in the prediction of patient outcomes from tamoxifen therapy remains controversial. This study evaluated the association between CYP2D6 genotypes and postoperative tamoxifen treatment outcome in patients with breast cancer, using the available previous study results. MATERIALS &

METHODS: We performed a meta-analysis of ten previous clinical reports (n = 5183) to evaluate the association between CYP2D6 genotype and hazard ratios for the recurrence risk of breast cancer after postoperative tamoxifen treatment. Pooled estimates of hazard ratios were computed using R and NONMEM짰 software.

RESULTS: A significantly increased risk of breast cancer recurrence in patients carrying variant CYP2D6 genotypes was found in this investigation. The mean hazard ratios and 95% CI were 1.60 (1.04-2.47) in the random effect model implemented in R and 1.63 (1.01-2.62) in the random effect model in NONMEM. The bootstrap result (2000 replicates) of NONMEM was 1.64 (1.07-2.79). CONCLUSION: Our present findings suggest that genetic polymorphisms of CYP2D6 may be important predictors of the clinical outcomes of adjuvant tamoxifen treatment for the patients with breast cancer. A large-scale, prospective, randomized, well-controlled trial is warranted to confirm our findings.

adjuvant; breast cancer; CYP2D6; hazard ratio; recurrence risk; tamoxifen

MESH

Breast Neoplasms/*drug therapy/genetics/pathology, Cytochrome P-450 CYP2D6/*genetics, Female, Genetic Association Studies, Humans, Neoplasm Recurrence, Local/*drug therapy/genetics, Prognosis, Tamoxifen/*administration & dosage, Treatment Outcome

링크

PubMed

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

A significantly increased risk of breast cancer recurrence in patients carrying variant CYP2D6 genotypes was found; genetic polymorphisms of CYP2D6 may be important predictors of the clinical outcomes of adjuvant tamoxifen treatment for the patients with breast cancer.

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

KCD코드

ICD 03

건강보험코드